Transcription inhibitors in inflammation

Bibliography

• FELDMANN M, BRENNAN FM, MAINI RN: Rheumatoid arthritis. Cell (1996) 85:307-310.An excellent review of molecular and cellular mechanisms of chronic joint inflammation in RA.
   Google Scholar
• FIRESTEIN GS: Cytokine networks in rheumatoid arthri-tis: implications for therapy. Agents Actions (1995) S47: 37–51.
   Google Scholar
• AREND WP, DAYER J: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-a in rheumatoid arthritis. Arthr. Rheum. (1995) 38(2):151–160.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal anti-bodies to tumor necrosis factor alpha. Arthr. Rheum. (1993) 12:1681–1690.
   Web of Science ®Google Scholar
• CAMPION GV, LEBSACK ME, LOOKABAUGH J et al: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist inpatients with rheu-matoid arthritis. Arthr. Rheum. (1996) 39(7):1092–1101.
   PubMed Web of Science ®Google Scholar
• SHAH A, CHURCH MK, HOLGATE ST: Tumor necrosis factor alpha-a potential mediator of asthma. Clin. Exp. Allergy (1995) 25:1038-1044.Review on the role of TNF and gene expression in asthma.
   Google Scholar
• BRADDING P, ROBERTS JA, BRITTEN KM et al: Inter-leukin-4, -5 and -6 and tumor necrosis factora in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. (1994) 10:471–480.
   PubMed Web of Science ®Google Scholar
• KONNO S, GONOKAMI Y, KUROKAWA M et al.: Cytokine concentrations in sputum of asthmatic patients. Int Arch. Allergy Immunol. (1996) 109:73–78.
   PubMed Web of Science ®Google Scholar
• LUKACS NW, STREITER RM, CHENSUE SW, WIDMER M,KUNKEL SL: TNF-a mediates recruitment of neutrophils and eosinophils during airway inflammation. J. Immu-nol. (1995) 154:5411–5417.
   PubMed Web of Science ®Google Scholar
• CHIOU GCY, LIU SXL: Novel, non-traditional, non-steroi-
   Google Scholar
• ?dal, anti-inflammatory agents. Exp. Opin. Ther. Patents (1996) 6(0:41-56.Review covering a broad range of anti-inflammatory agents under development, focusing upon recent patent applications covering matter of composition of different drug candidates.
   Google Scholar
• CARLOS T, HARLAN JM: Leukocyte-endothelial adhesion molecules. Blood (1994) 84:2068-2101.Review of mechanisms and regulation of leukocyte recruitment to sites of inflammation.
   Google Scholar
• JOHNSON BA, HAINES GK, HARLOW LA, KOCH AE: Adhe-sion molecule expression in human synovial tissue. Arthr. Rhem. (1993) 36:137–146.
   PubMed Web of Science ®Google Scholar
• TAK PP, THURKOW, EW, DAHA, MR et al.: Expression ofadhesion molecules in early rheumatoid synovial tis-sue. Clin. Immunol. Immunopathol. (1995) 77(3):236–242
   PubMedGoogle Scholar
• KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthr. Rheum. (1994) 37:992–999.
   PubMed Web of Science ®Google Scholar
• Isis' positive Crohn's disease trial. Scrip (1997) 2212:23.
   Google Scholar
• COLLINS T, READ MA, NEISH AS et al: Transcriptional regulation of endothelial cell adhesion molecules: NE-x13 and cytokine-inducible enhancers. FASEB J. (1995) 9:899–909.
   PubMed Web of Science ®Google Scholar
• CHEN CC, MANNING AM: Transcriptional regulation ofendothelial cell adhesion molecules: a dominant role for NF-x13. Agents Actions (1995) S47:135–141.
   Google Scholar
• TAK PP, TAYLOR PC, BREEDVELD FC et al. Decrease incellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthr. Rheum (1996) 39(7):1077–1081.
   PubMed Web of Science ®Google Scholar
• LEWIS AJ, KEFT AF: A review on the strategies for the development and application of new anti-arthritic agents. Immunopharm. Immunotoxicol (1995) 17 (4):607-663.Review of current strategies and development status of new disease-modifying agents, focusing on current activity within the pharma-ceutical industry.
   Google Scholar
• FIRESTEIN GS, PAINE MM, LITTMAN BH: Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and ef-fect of intraarticular corticosteroids. Arthr. Rheum. (1994) 34:1094–1105.
   Web of Science ®Google Scholar
• MANNING AM: Transcription factors: a new frontier for drug discovery. Drug Disc. Today (1996) 1(4):151-160.Primer on the role of TFs in disease, mechanisms of TF regulation and strategies for new drug development.
   Google Scholar
• KARIN M: Signal transduction from the cell surface to the nucleus through the phosphorylation of transcrip-tion factors. Curr. Opin. Cell Biol. (1994) 6:415–424.
   PubMed Web of Science ®Google Scholar
• MOBLEY JL, CHIN JE, RICHARDS IM: Glucocorticosteroids, old and new: biological function and use in the treatment of asthma. Exp. Opin. Invest. Drugs (1996) 5 (7):871–884.Recent review covering the mechanisms of action of GCs.
   Google Scholar
• ROSEN J, DAY A, JONES TK et al.: Intracellular receptors and signal transducers of transcription superfamilies: novel targets for small molecule drug discovery. J. Med. Chem. (1995) 38:4855–4874.
   PubMed Web of Science ®Google Scholar
• MANGELSDORF DJ, THUMMEL C, BEATO M et al: The nuclear receptor superfamily: the second decade. Cell (1995) 83:835–839.
   PubMed Web of Science ®Google Scholar
• CATO ACB, WADE E: Molecular mechanisms of anti-in-flammatory action of glucocorticoids. BioEssays (1996) 18:371–380.
   PubMed Web of Science ®Google Scholar
• LENARDO MJ, BALTIMORE D: NF-icB: a pleiotropic media-tor of inducible and tissue-specific gene control. Cell (1989) 58:227–229.
   PubMed Web of Science ®Google Scholar
• BAEUERLE PA, HENKEL T: Function and activation ofNF-icB inthe immune system. Ann. Rev. Immunol. (1994) 12:141–179.
   PubMed Web of Science ®Google Scholar
• MANNING AM, ANDERSON DC: Transcription factor NF-KB: an emerging regulator of inflammation. Ann. Rep. Merl. Chem. (1994) 29:235–244.
   Web of Science ®Google Scholar
• AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERG A, KARIN M: Immunosuppression by glucocorticoids: in-hibition of NF-icB activity through induction of IicB-a synthesis. Science (1995) 270:286–290.
   PubMed Web of Science ®Google Scholar
• SCHEINMAN RI, CROSSVVELL PC, LOFTQUIST AK BALD-WIN AS: Role of transcriptional activation of IicB-a in mediation of the immunosuppression by glucocorti-coids. Science (1995) 270:283–286.
   PubMed Web of Science ®Google Scholar
• ANGEL P, KARIN M: The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Bio-chem. Biophys. Acta. (1991) 1072:129–157.
   PubMed Web of Science ®Google Scholar
• MANNING AM, LEWIS AJ: Transcription factors, rheuma-toid arthritis and the search for improved antirheu-matic agents. Rheum. Arthr. (1997) 1:65–73.
   Google Scholar
• STEIN B, ANDERSON D: The MAP kinase family: new
   Google Scholar
• ••`MAPs' for signal transduction pathways and noveltargets for drug discovery. Ann. Rep. Merl. Chem. (1996) 31:289-298.Concise description of MAPK function and the potential for drug discovery.
   Google Scholar
• HECK S, KULLMANN M, GAST A, PONTA H etaL: A distinct modulating domain in glucocorticoid receptor mono-mers in the repression of activity of the transcription factor AP-1. EMBOJ (1994) 13:4087–4095.
   PubMed Web of Science ®Google Scholar
• SHAW KT, HO AM, RAGHAVAN A eta": Immunosuppres-sive drugs prevent a rapid dephosphorylation of tran-scription factor NFAT1 in stimulated immune cells. Proc. NaL Acad Sci. USA (1995) 92:11205–11209.
   PubMed Web of Science ®Google Scholar
• LUO C, SHAW KT, RAGHAVAN A et al: Interaction ofcalcineurin with a domain of the transcription factor NFAT, that controls nuclear import. Proc. Nat. Acad. Sci. USA (1996) 93:8907–8912.
   PubMed Web of Science ®Google Scholar
• RAO A: NF-ATp: a transcription factor required for the coordinate induction of several cytokine genes. Immu-nol Today (1994) 15:274-281.Recent review of NF-AT biology.
   Google Scholar
• LIU J, FARMER JD, LANE WS et al.: Calcineurin is acommon target for cyclophilin-cyclosporin A and FKBP-FK506 complex. Cell (1991) 66:807–815.
   PubMed Web of Science ®Google Scholar
• SEVVELL TJ, LAM E, MARTIN MM et al.: Inhibition ofcalcineurin by a novel FK506-binding protein. J. Biol. Chem. (1994) 269:21094–21102.
   PubMed Web of Science ®Google Scholar
• BRAM J, HUNG DT, MARTIN PK, SCHREIBER SL, CRABTREEGR: Identification of the immunophilins capable of mediating inhibition of signal transduction by cy-closporin A and FK506: role of calcineurin binding and cellular location. Mol. Cell Biol. (1993) 13:4760–4769.
   PubMed Web of Science ®Google Scholar
• PASERO G, PRIOLO F, MARUBINI E et al: Slow progressionof joint damage in early onset rheumaoid arthritis treated with cyclosporin A. Arthr. Rheum. (1996) 39:1006–1015.
   PubMed Web of Science ®Google Scholar
• DUMONT FJ, STARUCH MJ, KOPRAK SL et al: The immu-nosuppressive and toxic effects of FK-506 are mechan-istically related pharmacology of a novel antagonist of FK-506 and rapamycin. J. Exp. Med. (1992) 176:751–760.
   PubMed Web of Science ®Google Scholar
• HOWE LR, WEISS A: Multiple kinases mediate T-cellreceptor signaling. Trends Biochem. Sci. (1995) 20:59–64.
   PubMed Web of Science ®Google Scholar
• SHIBASAKI F, PRICE ER, MILAN D, MCKEON F: Role ofkinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NFAT4. Nature (1996) 382:370–373.
   PubMed Web of Science ®Google Scholar
• DAVIDSEN SK, SUMMERSJB: Inhibitors of TNF-a synthe-sis. Exp. Opin. Ther. Patents (1995) 5(10):1087–1100.
   Google Scholar
• MODUR V, ZIMMERMAN GA, PRESCOTT SM, MCINTYRETM: Endothelial cell inflammatory responses to tumor necrosis factor a. J. Biol. Chem. (1996) 271:13094–13102.
   PubMed Web of Science ®Google Scholar
• HAN J, LEE JD, BIBBS L, ULEVITCH RJ: A MAP kinasetargeted by endotoxin and hyperosmolarity in mam-malian cells. Science (1994) 265:808–811.
   PubMed Web of Science ®Google Scholar
• BOEHM JC, SMIETANA JM, SORENSON ME et al: 1-Substi-tuted 4-aryl-5-pridinylimidazoles: a new class of cytok-ine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitor potency. J. Med. Chem. (1996) 39:3929-3937.Concise description of the discovery of CSAIDs and the strategy for lead optimisation.
   Google Scholar
• LANTOS I, BENDER PE, RAZGAITIS KA et al.: Antiinflam-matory activity of 5,6-diary1-2,3-dihydroimidazo[2,1-b]thiazoles. Isomeric 4-pyridyl and 4-substituted phenyl derivatives. J. Med. Chem. (1984) 27:72–75.
   Google Scholar
• GALLAGHER TM, FIER-THOMPSON SM et al.: 2,4,5-tri-arylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Merl. Chem. Lett. (1995) 5:1171–1176.
   Web of Science ®Google Scholar
• TONG L, PAV S, WHITE DM et al.: A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. (1997) 4:311–316.
   PubMedGoogle Scholar
• KASZUBSKA W, HOOFT VAN HUIJSDUIJNEN R, GHERSA P et al.: Cyclic AMP-independent ATF family members interact with NF-kB and function in the activation of the E-selectin promoter in response to cytokines. Mol. Cell Biol. (1993) 13:7180–7190.
   Google Scholar
• GUPTA S, CAMPBELL D, DERIJARD B, DAVIS RJ: Transcrip-tion factor ATF2 regulation by the JNK signal transduc-tion pathway. Science (1995) 267:389–393.
   PubMed Web of Science ®Google Scholar
• STEIN B, BRADY H, YANG MX, YOUNG D, BARBOSA MG: Cloning and characterization of MEK6, a novel member of the MAP kinase cascade.' Biol. Chem. (1996) 271:11427–11433.
   Web of Science ®Google Scholar
• DUDLEY DT, PANG L, DECKER SJ, BRIDGES AJ, SALTIEL
   Google Scholar
• ••AR: A synthetic inhibitor of the mitogen-activated pro-tein kinase cascade. Proc. Nat. Acad. Sci. USA (1995) 92:7686-7689.Description of the discovery of MEK1 inhibitor and initial charac-terization.
   Google Scholar
• WHEELER-JONES CP, MAY MJ, HOULISTON RA, PEARSONJD: Inhibition of MAP kinase kinase (MEN blocks en-dothelial PGI2 release but has no effect on von Wille-brand factor secretion or E-selectin expression. FEBS Lett. (1996) 388:180–184.
   PubMed Web of Science ®Google Scholar
• GOLDMAN ME, RANSONE LJ, ANDERSON DW et al:
   Google Scholar
• ••SP100030 is a novel T-cell-specific transcription factorinhibitor that possesses immunosupp res sive activity in vivo. Trans. Proc. (1996) 28:3106-3109.Initial report of novel inhibitor of NF-IcB and AP-1, focusing upon efficacy in animal models of inflammation and transplant rejection.
   Google Scholar
• BOSCHELLI DH, KRAMER JB,KHATANA SS etal: Inhibition of E-selectin-, ICAM-1-, and VCAM-1-mediated cell adhe-sion by benzo[b]thiophene-, benzofuran-, indole- and napthalene-2-carboxamides: identification of PD 144795 as an anti-inflammatory agent. J. Med. Chem. (1995) 38:4597-4614.Extensive description of the synthesis and activity of PD 144795.
   Google Scholar
• WOELLE J, FERGUSON E, KESHAVA et al.: Inhibition of tumor necrosis factor induced aortic endothelial cell adhesion molecule gene expression by an alkoxy-benzo[b]thiophene-2-carboxamide. Biochem. Biophys Res. Comm. (1995) 214:6–10.
   PubMed Web of Science ®Google Scholar
• FENTEANY GF, STANDAERT RF, LANE WS etal.: Inhibition of protea some activities and subunit-specific amino-ter-minal threonine modification by lactacystin. Science (1995) 268:726-731.Excellent example of the identification of the molecular mechanism of action of a known agent.
   Google Scholar
• PALOMBELLA VJ, RANDO OL, GOLDBERG AL, MANIATIS T: The ubiquitin-proteasome pathway is required for processing the NF-al precursor protein and the acti-vation of NF-KB. Cell (1994) 78:773–785.
   PubMed Web of Science ®Google Scholar
• MAKI CG, HUIBREGTSE JM, HOWLEY PM: In vivo ubiquit-ination and proteasome-mediated degradation of p53. Cancer Res. (1996) 56:2649–2654.
   PubMed Web of Science ®Google Scholar
• KIM TK, MANIATIS T: Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science (1996) 273: 1717-1719.
   Google Scholar
• READ MA, NEISH AS, LUSCINSKAS FW et al.: The protea-some pathway is required for cytokine-induced endo-thelial leukocyte adhesion molecule expression. Immu-nity (1995) 2:493–506.
   Web of Science ®Google Scholar
• DREXLER HC: Activation of the cell death program by inhibition of proteasome function. Proc. Nat Acad. Sci. USA (1997) 94:855–860.
   PubMed Web of Science ®Google Scholar
• ENDRESS S, FULLE H, SINHA B et al.: Cyclic nucleotides differentially regulate the synthesis of tumor necrosis factor a and interleukin lb by human mononuclear cells. Immunology (1991) 72:56–60.
   PubMed Web of Science ®Google Scholar
• KATAKAMI Y, NAKAO Y, KOIZUMI T et al: Regulation of tumor necrosis factor production by mouse peritoneal macrophages: the role of cyclic AMP. Immunology (1988) 64:719–724.
   PubMed Web of Science ®Google Scholar
• PALFREYMAN MN: P hosp ho die ste ras e type IV inhibitors as antiinflammatory agents. Drugs Future (1995) 20:793-804.Recent review of drug discovery activities.
   Google Scholar
• GADANGI P, LONGAKER M, NAIME D et al: The anti-in-flammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol (1996) 156:1937–1941.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN, EBERLE MA, GRUBER HE, LEVIN RI:Methotrexate inhibits neutrophil function by stimulat-ing adenosine release from connective tissue cells. Proc. Nat Acad. Sci. USA (1991) 88:2441–2445.
   PubMed Web of Science ®Google Scholar
• ROSENGREN S, BONG GW, FIRESTEIN GS: Anti-inflamma-tory effects of an adenosine kinase inhibitor. J. Immunol. (1995) 154:5444–5451.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN GS, BOYLE D, BULLOUGH DA et al.: Protective effect of an adenosine kinase inhibitor in septic shock. Immunol. (1994) 152:5853–5859.
   Web of Science ®Google Scholar
• BOYLE D, SAJJADI FG, FIRESTEIN GS: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthr. Rheum. (1996) 39:923–930.
   PubMed Web of Science ®Google Scholar
• RICE GW, GUIDOT D, REPINE Jet al.: Central role for the second messenger phosphatidic acid in cytokine medi-ated inflammatory diseases. Eur. Cyto. Netw. (1994) 5:198–211.
   Google Scholar
• ABRAHAM E, BURSTEN S, SHENKAR R et al: Phosphatidic acid signalling mediates lung cytokine expression and lung inflammatory injury after haemorrhage in mice. J. Exp. Med. (1995) 181:569–575.
   PubMed Web of Science ®Google Scholar
• RICE G, BROWN P, NELSON RJ et al: Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc. Nat Acad. Sci. USA (1994) 91:3857–3861.
   PubMed Web of Science ®Google Scholar
• MOSSMAN TR: Properties and function of interleukin-10. Adv. Immunol. (1994) 56:1–26.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, OTSUKA T, HOTOKEBUCHI T eta].: Effect of IL-10 on collagen-induced arthritis in mice. In/lam. Res. 45:283–288.
   Google Scholar
• CHERNOFF AE, GRANOWITZ EV, SHAPIRO L et al.: Arandomized, controlled trial of 1L-10 in humans: inhi-bition of inflammatory cytokine production and im-mune response. J. Immunol (1995) 154:5492–5499.
   PubMed Web of Science ®Google Scholar
• WANG P, WU P, SIEGEL MI, EGAN RW, BILLAH MM: Interleukin-10 inhibits nuclear factor kappa B (NF-d3) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. 270:9558-9563.
   Google Scholar
• FINBLOOM DS, WINESTOCK KD: IL-10 induces tyrosine phosphorylation of tyk2 and Jakl and the differential assembly of STATla and STAT3 complexes in human T-cells and monocytes. j Immunol. (1995) 155:1079–1090.
   PubMed Web of Science ®Google Scholar
• GONZALES RS, BENNETT BL, ROSENBLOOM CL, ANDER-SON DC, MANNING AM: Anti-inflammatory effects of IL-10 are cell-type specific and independent of NF-x13. FASEB j (1997) 11:A196.
   Web of Science ®Google Scholar
• HOU J, SCHINDLER U, HENZEL WJ et al.: An interleukin 4-induced transcription factor IL-4 STAT. Science (1994) 265: 1701-1706.
   Google Scholar
• BENNETT BL, CRUZ R, LACSON RG, MANNING AM: Inter-leukin-4 suppression oftumor necrosis factor a-stimu-lated E-selectin gene transcription is mediated by STAT6 antagonism of NF-KB. j Biol. Chem. (1997) 272:10212–10219.
   PubMed Web of Science ®Google Scholar
• Burning up the citation logs. Science (1997) 275:1573.
   PubMedGoogle Scholar